


SEP 28 1932

# The British Medical Journal

THE JOURNAL OF THE BRITISH MEDICAL ASSOCIATION



*Including an Epitome of Current Medical Literature*  
WITH SUPPLEMENT

No. 3741

SATURDAY, SEPTEMBER 17, 1932

Price 1/3



## *The Serum Treatment of Ulcerative Colitis*

THE researches of Bargen and his co-workers at the Mayo Clinic on ulcerative colitis led them to advance the view that a non-haemolytic streptococcus is the factor of primary etiological importance in this disease. Later work has done much to confirm the original findings.

In consequence, it has been possible to develop a specific Ulcerative Colitis Antistreptococcus Serum which has been used clinically with very favourable results.

In the preparation of this serum Parke, Davis & Co. follow the method developed by Bargen, and have the advantage of using fresh cultures supplied by Bargen himself.

The dose of the serum should not be more than 2 c.c. to commence with, and this may be increased up to 5 c.c., injected either intramuscularly or intravenously, at intervals of 12 hours.

## ULCERATIVE COLITIS ANTISTREPTOCOCCUS SERUM (P., D. & Co.)

*Supplied in vials of 20 c.c. Further particulars will be sent on request.*

PARKE, DAVIS & CO., 50 BEAK STREET, LONDON, W.1.

Laboratories: Hounslow, Middlesex. Inc. U.S.A., Liability Ltd.